Year: 2022

Vertex Providing Refunds for 340B Overcharges on Cystic Fibrosis Drug Trikafta

February 1, 2022 Tom Mirga, Editor at Large Views

Vertex Pharmaceuticals is giving 340B covered entities refunds for overcharges from Q2 2021 through Q4 2021 on its cystic fibrosis combination medicine Trikafta.

Biopharmaceutical company Vertex is providing refunds to 340B covered entities for overcharges on its cystic fibrosis (CF) combination medicine Trikafta for the period from Q2 2021 through Q4 2021, according to a public notice on the U.S. Health Resources and

…

340B Report Publisher and CEO Forecasts What to Expect After November Congressional Elections

February 1, 2022 Tom Mirga, Editor at Large Views

AHA and RWC-340B again took aim at the 340B ACCESS Act introduced this spring.

340B Report Publisher and Chief Executive Officer Ted Slafsky says in his latest column for Omnicell’s blog that “all signs foretell a Republican takeover of the House and a very good possibility of the GOP assuming control of the closely

…

News Alert: Pfizer Becomes the 13th Drug Maker to Limit 340B Contract Pharmacies

January 28, 2022 Tom Mirga, Editor at Large Views

Pfizer is the 13th drug manufacturer to impose conditions on 340B sales of prescription drugs involving contract pharmacies.

UPDATE Friday, Jan. 28, 2022, 3:25 p.m.—The U.S. Health Resources and Services Administration (HRSA) said this afternoon it is reviewing Pfizer’s policy and will evaluate next steps as needed.

Pfizer today became the 13^th drug manufacturer to impose conditions on

…

Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price

January 27, 2022 Tom Mirga, Editor at Large Views

Bristol Myers Squibb said Jan. 14 it voluntarily will let 340B covered entities buy Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through specialty pharmacies in the company's limited distribution network for the drugs. BMS acquired the drugs in 2019 when it acquired Celgene. In 2017, HRSA told Celgene it had to ensure that 340B entities could buy the drugs at 340B price through the same limited distribution network.

The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited

…

Novo Nordisk Will Let Hospitals Designate Two 340B Contract Pharmacies—one Retail and one Specialty

January 27, 2022 Tom Mirga, Editor at Large Views

Novo Nordisk has amended its policy restrictions on 340B drug sales to hospitals. Starting Feb. 1, it will let those lacking wholly owned contract pharmacies to designate two contract pharmacy locations—one retail and one specialty.

Drug manufacturer Novo Nordisk has amended its policy restrictions on 340B drug sales to hospitals involving shipments to contract pharmacies.

In a notice to covered entities dated Jan. 24, Novo Nordisk said if a 340B hospital covered entity “does

…

In a Relief to Rural Providers, Gilead Is Waiving 340B Orphan Drug Exclusion for its COVID-19 Drug Veklury

January 27, 2022 Tom Mirga, Editor at Large Views

Gilead says it will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19.

Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.

The U.S. Food and Drug Administration (FDA)

…

Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says

January 27, 2022 Tom Mirga, Editor at Large Views

340B Health says a new survey of its members shows 340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies.

UPDATE Friday, Jan. 28, 2022—This story was updated to include comments by Pharmaceutical Research and Manufacturers of America (PhRMA.)

340B hospitals “are losing significant resources” due to drug companies’ conditions on 340B pricing when covered entities use contract pharmacies, according

…

Vizient Asks Congress to Pass Senate Version of Bill to Protect Hospitals from Losing 340B Eligibility During Pandemic

January 27, 2022 Tom Mirga, Editor at Large Views

Vizient asked Congress to pass the U.S. Senate version of bipartisan legislation to protect hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the COVID-19 pandemic.

Health care services and group purchasing company Vizient asked Congress on Monday to pass the U.S. Senate version of bipartisan legislation to protect hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the

…

340B PROVIDER LEADER SPOTLIGHT

Julie Valdes, Clinical Pharmacist & 340B Program Coordinator, Zufall Health Centers Inc.

January 27, 2022 Diane Slafsky Views

Q: Where did you go to college/graduate school?

For college, I went to Occidental College in Los Angeles, California and majored in Biochemistry. For graduate school, I went to

…

Bipartisan U.S. House Group Wants HHS to Start Punishing Drug Makers Over 340B Pricing Denials

January 25, 2022 Tom Mirga, Editor at Large Views

headshots of U.S. House leaders Spanberger, Axne, McKinley, Matsui, Katko, Johnson

Clockwise from top left, U.S. Reps. Abigail Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) asked HHS “to move quickly to enforce the law and begin assessing civil monetary penalties on manufacturers that have denied 340B pricing to providers.”

Three Democratic and three Republican U.S. House members asked the U.S. Health and Human Services Department (HHS) on Friday “to move quickly to enforce the law and begin assessing civil monetary penalties on manufacturers that have denied 340B pricing to

…

340B PROVIDER LEADER SPOTLIGHT

Site Footer Live